BriaCell Therapeutics (TSE:BCT) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BriaCell Therapeutics reports a breakthrough in treating a breast cancer patient with severe brain metastasis, achieving complete resolution of the tumor in the brain after 8 and 11 months of treatment. The patient, who had not responded to 8 previous treatments, showed significant tumor reduction with BriaCell’s Bria-IMT™ regimen and continues to make progress.
For further insights into TSE:BCT stock, check out TipRanks’ Stock Analysis page.